Transcription News and Research

RSS

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

OncoGenex Pharmaceuticals, Inc., announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as custirsen (OGX-011) that is designed to knock down treatment resistance in the cells and enhance the effectiveness of cancer therapies.

1 Mar 2010

Axolotl celebrates 15 years of software development and HIE implementation

Axolotl Corp., the nationwide leader in health information exchange (HIE) services and solutions, celebrates fifteen successful years of software development and HIE implementation. Since its founding in 1995, Axolotl has been providing advanced Clinical Networking™ solutions to meet the diverse and changing needs of physicians, hospitals, regional health information organizations (RHIOs) and statewide HIEs to achieve interoperability across entire medical trading areas.

1 Mar 2010

Body repairs itself through microvesicles: New hope for tissue regeneration

Researchers at Rhode Island Hospital have discovered how cells communicate with each other during times of cellular injury. The findings shed new light on how the body repairs itself when organs become diseased, through small particles known as microvesicles, and offers hope for tissue regeneration.

27 Feb 2010

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Marking a shift in decades of thought on the cause of osteoporosis, researchers at the University of Arkansas for Medical Sciences have identified an age-related mechanism - not a decrease of the hormone estrogen - as the primary culprit.

27 Feb 2010

Mutations in MeCP2 cause autism spectrum disorder Rett Syndrome

A paper published online today in Molecular Cell proposes that Methyl CpG binding protein 2 (MeCP2) impacts the entire genome in neurons, rather than acting as a regulator of specific genes. Mutations in MeCP2 cause the autism spectrum disorder Rett Syndrome as well as some cases of neuropsychiatric problems including autism, schizophrenia and learning disabilities.

26 Feb 2010

Nightingale reports revenue of $4.4M for third-quarter fiscal 2010

Nightingale Informatix Corporation, an application service provider (ASP) of electronic medical record (EMR) software and related services announces its financial results for the quarter and nine months ended December 31, 2009. All results are reported in Canadian dollars unless otherwise stated.

25 Feb 2010

Biochemical link between misery and death discovered

In ongoing work to identify how genes interact with social environments to impact human health, UCLA researchers have discovered what they describe as a biochemical link between misery and death. In addition, they found a specific genetic variation in some individuals that seems to disconnect that link, rendering them more biologically resilient in the face of adversity.

25 Feb 2010

Arsenic exposure may increase cancer risk, says study

Researchers have found a new oncogenic signaling pathway by which the environmental toxin arsenic may lead to adverse health effects, including bladder cancer. These study results are published in Cancer Research, a journal of the American Association for Cancer Research.

24 Feb 2010

Study may help in defining better therapeutic strategies for oral and throat cancer

Mayo Clinic researchers along with collaborators from Life Technologies are reporting on the application of a new approach for sequencing RNA to study cancer tumors. Their findings from a proof-of-principle study on oral carcinomas appear in the current issue of PLoS One, the online science journal.

24 Feb 2010

Medquist to particpate as Implementer in the HIMSS10 Interoperability Showcase

Demonstrating the value of standards-based health information technologies, MedQuist Inc., a leading provider of technology-enabled clinical documentation services, is participating as an Implementer in the HIMSS10 Interoperability Showcase at booth #233 in Hall C of the Georgia World Congress Center in Atlanta, Georgia. The Showcase is part of the 2010 Annual Healthcare Information and Management Systems Society Conference & Exhibition being held from March 1-4.

23 Feb 2010

Major challenge facing today's toxicologists: Developing test systems to predict toxicity of compounds

Attagene Inc., a leader in developing innovative technologies for analyzing gene regulatory pathways, announced today the online publication of a paper in Chemical Research in Toxicology, a journal of the American Chemical Society, that highlights results of their collaborative work with the Environmental Protection Agency's National Center for Computational Toxicology (NCCT).

19 Feb 2010

PharmaTelevision launches major new services to meet growing demands of pharmaceutical industry

PharmaTelevision Ltd announced today the launch of major new services to meet the growing demand for the production and dissemination of rich media content in the pharmaceutical and biotechnology sector. The company, a subsidiary of PharmaVentures, already provides the only online television channel dedicated to the bio-pharma industry, offering daily television news, analysis and feature interviews.

19 Feb 2010

Mechanism by which Plasmodium replicates itself in human blood to spread disease identified

Malaria remains one of the most deadly infectious diseases. Yet, how Plasmodium, the malaria parasite, regulates its infectious cycle has remained an enigma despite decades of rigorous research.

19 Feb 2010

Asuragen announces agreement to develop and manufacture RNA Control Kits for Affymetrix

Asuragen Inc., a leading molecular biology diagnostic company and service provider, today announced an agreement to develop and manufacture RNA Control Kits for Affymetrix. The RNA Control Kit is intended for use with in vitro transcription (IVT) reagent kits for clinical molecular diagnostic applications that Asuragen has licensed and supplied to Affymetrix.

18 Feb 2010

Researchers find new risk factor for early-onset dementia

Examining brain tissue from over 500 individuals in 11 countries, researchers from the University of Pennsylvania School of Medicine and the Children's Hospital of Philadelphia, and colleagues found a new risk factor for the second-most-common cause of early-onset dementia after Alzheimer's disease.

16 Feb 2010

SRC-3 gene sends signal to cell membrane to promote cell motility

The master gene called SRC-3 (steroid receptor coactivator 3) not only enhances estrogen-dependent growth of cancer cells by activating and encouraging the transcription of a genetic message into a protein, it also sends a signal to the cell membrane to promote cell motility or movement - a key element of cancer spread or metastasis, said Baylor College of Medicine (www.bcm.edu) researchers and collaborators in a report that appears in the current issue of the journal Molecular Cell.

15 Feb 2010

MacSpeech Scribe Medical add-on component released

MacSpeech, Inc. today announced MacSpeech Scribe Medical, an add-on component that incorporates the world's most advanced personal transcription for the Macintosh with MacSpeech Dictate Medical, the medical professional's speech recognition solution for the Macintosh.

12 Feb 2010

Study: New mechanism may allow bacteria to develop resistance to antibiotics

Scientists have shown that cells' DNA-reading machinery can skim through certain kinds of damaged DNA without skipping any letters in the genetic "text." The studies, performed in bacteria, suggest a new mechanism that can allow bacteria to develop resistance to antibiotics.

10 Feb 2010

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

MedQuist to acquire Spheris' domestic business

MedQuist Inc., a leading provider of medical transcription software and services, today announced that it has agreed to purchase the domestic business of Spheris Inc., a global provider of clinical documentation technology and services that recently filed for Chapter 11 bankruptcy protection.

4 Feb 2010